Puma Biotechnology Inc., based in Westwood, has struck an up-to-$35-million deal with Pint Pharma International to commercialize its signature cancer drug in Latin America.

Puma announced this week it had struck a licensing agreement with the Switzerland-based firm to gain entry into the Central and South American markets.

Pint Pharma will seek regulatory approval to sell Puma’s Nerlynx drug for HER2-positive breast cancer from Mexico to Argentina. The drug has yet to be approved outside the U.S.

Puma will receive up to $34.5 million in upfront and milestone payments, plus double-digit royalties on its cancer drug, also known as Neratinib.

Health business reporter Dana Bartholomew can be reached at [email protected]. Follow him on Twitter @_DanaBart.